pyrazines has been researched along with Chromosomal Triplication in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bergsagel, PL; Chesi, M | 1 |
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R | 1 |
Ahmann, G; Bergsagel, PL; Bryant, B; Carpten, J; Chng, WJ; Chung, TH; Dispenzieri, A; Fonseca, R; Gertz, M; Greipp, P; Henderson, K; Kim, S; Kumar, S; Kyle, R; Lacy, M; Mulligan, G; Price-Troska, T; Rajkumar, SV; Vanwier, S | 1 |
1 review(s) available for pyrazines and Chromosomal Triplication
Article | Year |
---|---|
Molecular pathogenesis of multiple myeloma: basic and clinical updates.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosomes, Human; Cyclin D; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin M; Incidence; Multiple Myeloma; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Risk Factors; Sex Factors; Somatic Hypermutation, Immunoglobulin; Survival Rate; Translocation, Genetic; Trisomy; United States | 2013 |
1 trial(s) available for pyrazines and Chromosomal Triplication
Article | Year |
---|---|
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Diploidy; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Multigene Family; Multiple Myeloma; Prognosis; Protein Biosynthesis; Pyrazines; Trisomy | 2007 |
2 other study(ies) available for pyrazines and Chromosomal Triplication
Article | Year |
---|---|
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 1; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Thalidomide; Treatment Outcome; Trisomy | 2013 |